Boyle C. Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Boyle C. Cheng has a total of 410 co-authors. Here are the top co-authors by number of shared publications:
Daniel J. Cook
Department of Neurosurgery, Allegheny General Hospital, Pittsburgh, Pennsylvania
12 shared publications- Matthew S. Yeager
Department of Neurosurgery, Allegheny Health Network, Pittsburgh, Pennsylvania
12 shared publications - Daniel T. Altman
Allegheny General Hospital, Department of Orthopaedic Surgery, Pittsburgh, PA, USA
5 shared publications Donald M. Whiting
Department of Neurosurgery, Drexel University, Allegheny General Hospital, Pittsburgh, PA
5 shared publicationsMichael Y. Oh
Department of Neurosurgery, Allegheny General Hospital, Pittsburgh, Pennsylvania
5 shared publicationsWilliam C. Welch
Department of Neurosurgery, University of Pennsylvania, 3400 Spruce St., 3 Silverstein Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
5 shared publications
Latest Publications
- 1 November 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Biomedical Engineering
- Vol. 73 (11) , 3669-3679
Transnasal Implants in the Nasal Cavity and Sphenoid Sinus for Minimally Invasive Deep Brain Stimulation: Measurement of Electric Field in Cadavers
Deep brain stimulation (DBS) is increasingly used in treating motor disorders, neurodegenerative conditions, and mental health conditions. However, treatments are limited to the most severe cases due to the invasiveness of the surgical procedure. We propose stimulating ventral brain areas using electrodes inserted through the nose and placed in contact with the inferior skull base bones, under the olfactory cleft and in the sphenoid sinus. We designed a compact, low-power stimulation implant that fits in the sphenoid sinus and tested the implant insertion and operation in cadaveric heads, measuring the electric field obtained in deep brain regions. Using commercial multielectrode probes and an external stimulator, we also measured the electric field in cadaveric brains generated by different electrode placements to characterize the focus and steering that can be achieved. The implant can generate electric fields in the brain above 10 V/m, likely sufficient for neuronal activation. It is powered using either a 3 V battery which can generate almost 100 000 pulses from a 1 mAh charge, or alternatively, using inductive wireless power transfer, with the primary coil placed around the circumference of the head. This first-of-its-kind sphenoid implant demonstrates the possibility of minimally-invasive, focused deep brain stimulation. By enabling stimulation of deep brain regions without requiring surgery, transnasal stimulation can drastically improve the accessibility of some DBS treatments and broaden its applicability to additional mental health conditions.
- 1 November 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Biomedical Engineering
- Vol. 73 (11) , 3669-3679
Transnasal Implants in the Nasal Cavity and Sphenoid Sinus for Minimally Invasive Deep Brain Stimulation: Measurement of Electric Field in Cadavers
Deep brain stimulation (DBS) is increasingly used in treating motor disorders, neurodegenerative conditions, and mental health conditions. However, treatments are limited to the most severe cases due to the invasiveness of the surgical procedure. We propose stimulating ventral brain areas using electrodes inserted through the nose and placed in contact with the inferior skull base bones, under the olfactory cleft and in the sphenoid sinus. We designed a compact, low-power stimulation implant that fits in the sphenoid sinus and tested the implant insertion and operation in cadaveric heads, measuring the electric field obtained in deep brain regions. Using commercial multielectrode probes and an external stimulator, we also measured the electric field in cadaveric brains generated by different electrode placements to characterize the focus and steering that can be achieved. The implant can generate electric fields in the brain above 10 V/m, likely sufficient for neuronal activation. It is powered using either a 3 V battery which can generate almost 100 000 pulses from a 1 mAh charge, or alternatively, using inductive wireless power transfer, with the primary coil placed around the circumference of the head. This first-of-its-kind sphenoid implant demonstrates the possibility of minimally-invasive, focused deep brain stimulation. By enabling stimulation of deep brain regions without requiring surgery, transnasal stimulation can drastically improve the accessibility of some DBS treatments and broaden its applicability to additional mental health conditions.
- 27 April 2026
- Published by International Journal of Spine Surgery in International Journal of Spine Surgery
- Vol. 20 (2) , 243-244
Boundary Conditions Affecting Finite Element Analyses of a Spinal Segment
- 27 April 2026
- Published by International Journal of Spine Surgery in International Journal of Spine Surgery
- Vol. 20 (2) , 243-244
Boundary Conditions Affecting Finite Element Analyses of a Spinal Segment
- Open Access
- 24 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (43) , eadx4374
Vasa vasorum plexus formation in intracranial aneurysm associates with microcalcification and wall thickening
Intracranial aneurysms (IAs) affect about 3% of the population, often leading to catastrophic outcomes upon rupture. Vasa vasorum, microvessels supplying arterial walls, are conjectured to induce inflammation and leakage in IAs that drive adverse remodeling. Using scanning immunofluorescent multiphoton imaging and micro–computed tomography to visualize intact IA specimens, we identified an extensive vasa vasorum plexus in the IA wall. Our quantitative analyses show significant colocalization of vasa vasorum with calcifications, a strong correlation with increased wall thickness ( R 2 = 0.96, P < 0.001), and associations with well-defined multiaxially oriented collagen fibers. These findings highlight a more nuanced role for vasa vasorum, suggesting both adverse and protective remodeling influences, which may critically affect IA rupture risk. Contrary to the prevailing view of vasa vasorum as solely adverse, this study underscores the contribution to IA wall stability and the need to elucidate their functional impact on IA pathophysiology. Hence, these microvessels warrant further investigation for therapeutic targeting.
- 24 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (43) , eadx4374
Open AccessVasa vasorum plexus formation in intracranial aneurysm associates with microcalcification and wall thickening
Intracranial aneurysms (IAs) affect about 3% of the population, often leading to catastrophic outcomes upon rupture. Vasa vasorum, microvessels supplying arterial walls, are conjectured to induce inflammation and leakage in IAs that drive adverse remodeling. Using scanning immunofluorescent multiphoton imaging and micro–computed tomography to visualize intact IA specimens, we identified an extensive vasa vasorum plexus in the IA wall. Our quantitative analyses show significant colocalization of vasa vasorum with calcifications, a strong correlation with increased wall thickness ( R 2 = 0.96, P < 0.001), and associations with well-defined multiaxially oriented collagen fibers. These findings highlight a more nuanced role for vasa vasorum, suggesting both adverse and protective remodeling influences, which may critically affect IA rupture risk. Contrary to the prevailing view of vasa vasorum as solely adverse, this study underscores the contribution to IA wall stability and the need to elucidate their functional impact on IA pathophysiology. Hence, these microvessels warrant further investigation for therapeutic targeting.
- Open Access
- 1 October 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 5555-5565
Chemonucleolysis for Lumbar Disc Herniation: History and Current State of the Technology
The most common cause of radicular leg pain is lumbar disc herniation (LDH). LDH occurs when the central disc material, predominantly the nucleus pulposus, is displaced beyond the margins of the disc, compressing the spinal nerve roots and in turn causing radicular leg pain. Patients with persistent LDH symptoms that do not respond to conservative management have limited treatment options other than surgery. There has been a resurgence of interest in chemonucleolysis, in which an enzyme or other substance is directly injected into the intervertebral disc with the goal of reducing the size of the nucleus pulposus, relieving pressure on the nerve roots. Chemonucleolysis with chymopapain was widely used in the 1980s and 1990s as an effective treatment for LDH that was less invasive than surgery. Following the discontinuation of chymopapain in 1999, no chemonucleolytic therapy has been commercially available in the US. SI-6603 (condoliase) is a mucopolysaccharidase that selectively degrades chondroitin sulfate glycosaminoglycan (GAG) chains in the nucleus pulposus. Condoliase is approved in Japan and recently demonstrated significant improvements in worst leg pain (vs sham) in a pivotal US phase 3 clinical trial. Chemonucleolytic agents with less substrate specificity include gelified ethanol and oxygen-ozone, which are under postmarket surveillance in Europe, as well as collagenase in China. The re-emergence of chemonucleolysis is anticipated to improve the treatment landscape for LDH, providing patients with the option to avoid more invasive surgical intervention.
- 1 October 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 5555-5565
Open AccessChemonucleolysis for Lumbar Disc Herniation: History and Current State of the Technology
The most common cause of radicular leg pain is lumbar disc herniation (LDH). LDH occurs when the central disc material, predominantly the nucleus pulposus, is displaced beyond the margins of the disc, compressing the spinal nerve roots and in turn causing radicular leg pain. Patients with persistent LDH symptoms that do not respond to conservative management have limited treatment options other than surgery. There has been a resurgence of interest in chemonucleolysis, in which an enzyme or other substance is directly injected into the intervertebral disc with the goal of reducing the size of the nucleus pulposus, relieving pressure on the nerve roots. Chemonucleolysis with chymopapain was widely used in the 1980s and 1990s as an effective treatment for LDH that was less invasive than surgery. Following the discontinuation of chymopapain in 1999, no chemonucleolytic therapy has been commercially available in the US. SI-6603 (condoliase) is a mucopolysaccharidase that selectively degrades chondroitin sulfate glycosaminoglycan (GAG) chains in the nucleus pulposus. Condoliase is approved in Japan and recently demonstrated significant improvements in worst leg pain (vs sham) in a pivotal US phase 3 clinical trial. Chemonucleolytic agents with less substrate specificity include gelified ethanol and oxygen-ozone, which are under postmarket surveillance in Europe, as well as collagenase in China. The re-emergence of chemonucleolysis is anticipated to improve the treatment landscape for LDH, providing patients with the option to avoid more invasive surgical intervention.
- Open Access
- 4 February 2025
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 14 (2) , 77-92
Clinical efficacy and safety of P-15 peptide enhanced bone graft substitute in surgical bone regenerative procedures in adult maxillofacial, spine, and trauma patients
Aims: Autologous bone graft (ABG) is considered the ‘gold standard’ among graft materials for bone regeneration. However, complications including limited availability, donor site morbidity, and deterioration of regenerative capacity over time have been reported. P-15 is a synthetic peptide that mimics the cell binding domain of Type-I collagen. This peptide stimulates new bone formation by enhancing osteogenic cell attachment, proliferation, and differentiation. The objective of this study was to conduct a systematic literature review to determine the clinical efficacy and safety of P-15 peptide in bone regeneration throughout the skeletal system.Methods: PubMed, Embase, Web of Science, and Cochrane Library were searched for relevant articles on 13 May 2023. The systematic review was reported according to the PRISMA guidelines. Two reviewers independently screened and assessed the identified articles. Quality assessment was conducted using the methodological index for non-randomized studies and the risk of bias assessment tool for randomized controlled trials.Results: After screening, 28 articles were included and grouped by surgical indication, e.g. maxillofacial procedures (n = 18), spine (n = 9), and trauma (n = 1). Published results showed that P-15 peptide was effective in spinal fusion (n = 7) and maxillofacial (n = 11), with very few clinically relevant adverse events related to P-15 peptide.Conclusion: This systematic literature review concluded that moderate- (risk of bias, some concern: 50%) to high-quality (risk of bias, low: 46%) clinical evidence exists showing equivalent safety and efficacy in bone regeneration using a P-15 peptide enhanced bone graft substitute compared to ABG. P-15 peptide is safe and effective, resulting in rapid bone formation with a low probability of minor complications.Cite this article: Bone Joint Res 2025;14(2):77–92.
- 4 February 2025
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 14 (2) , 77-92
Open AccessClinical efficacy and safety of P-15 peptide enhanced bone graft substitute in surgical bone regenerative procedures in adult maxillofacial, spine, and trauma patients
Aims: Autologous bone graft (ABG) is considered the ‘gold standard’ among graft materials for bone regeneration. However, complications including limited availability, donor site morbidity, and deterioration of regenerative capacity over time have been reported. P-15 is a synthetic peptide that mimics the cell binding domain of Type-I collagen. This peptide stimulates new bone formation by enhancing osteogenic cell attachment, proliferation, and differentiation. The objective of this study was to conduct a systematic literature review to determine the clinical efficacy and safety of P-15 peptide in bone regeneration throughout the skeletal system.Methods: PubMed, Embase, Web of Science, and Cochrane Library were searched for relevant articles on 13 May 2023. The systematic review was reported according to the PRISMA guidelines. Two reviewers independently screened and assessed the identified articles. Quality assessment was conducted using the methodological index for non-randomized studies and the risk of bias assessment tool for randomized controlled trials.Results: After screening, 28 articles were included and grouped by surgical indication, e.g. maxillofacial procedures (n = 18), spine (n = 9), and trauma (n = 1). Published results showed that P-15 peptide was effective in spinal fusion (n = 7) and maxillofacial (n = 11), with very few clinically relevant adverse events related to P-15 peptide.Conclusion: This systematic literature review concluded that moderate- (risk of bias, some concern: 50%) to high-quality (risk of bias, low: 46%) clinical evidence exists showing equivalent safety and efficacy in bone regeneration using a P-15 peptide enhanced bone graft substitute compared to ABG. P-15 peptide is safe and effective, resulting in rapid bone formation with a low probability of minor complications.Cite this article: Bone Joint Res 2025;14(2):77–92.
- 28 November 2024
- Published by Elsevier in The Spine Journal
- Vol. 25 (5) , 929-938
Effect of industry funding on outcome reporting in cervical disc arthroplasty: a systematic review and meta-analysis of randomized controlled trials
- 28 November 2024
- Published by Elsevier in The Spine Journal
- Vol. 25 (5) , 929-938
Effect of industry funding on outcome reporting in cervical disc arthroplasty: a systematic review and meta-analysis of randomized controlled trials
- Open Access
- 6 September 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (9) , 898
Comparing the Immune Response to PEEK as an Implant Material with and without P-15 Peptide as Bone Graft Material in a Rabbit Long Bone Model
P-15 is a 15-amino-acid-long biomimetic peptide widely demonstrated to enhance osteogenesis in vivo. Despite the prevalence of polyether-ether-ketone (PEEK) in interbody device manufacturing, a growing body of evidence suggests it may produce an unfavorable immune response. The purpose of this preliminary study was to characterize the immune response and new bone growth surrounding PEEK implants with and without a P-15 peptide-based osteobiologic. A bilateral femoral defect model was conducted using New Zealand white rabbits. A total of 17 test subjects received one implant in each distal femur, either with or without bone graft material. Animals were allowed to survive to 4 or 8 weeks, at which time the femurs were collected and subjected to micro-computer tomography (microCT) or cytokine analysis. MicroCT analysis included the quantification of bone growth and density surrounding each implant. The cytokine analysis of periprosthetic tissue homogenates included the quantification of interleukins (ILs) and TNF-α expression via ELISA kits. Improvements in bone volume were observed in the P-15 cohort for the regions of interest, 500–136 and 136–0 µm from the implant surface, at 8 weeks post-op. Concentrations of IL-1β, IL-4, and IL-6 cytokines were significantly higher in the P-15 cohort compared to the PEEK cohort at the 4-week timepoint. Significant reductions in the concentrations of IL-4 and IL-6 cytokines from the 4- to 8-week cohort were observed in the P-15 cohort only. The P-15 peptide has the potential to modulate the immune response to implanted materials. We observed improvements in bone growth and a more active micro-environment in the P-15 cohort relative to the PEEK control. This may indicate an earlier transition from the inflammatory to remodeling phase of healing.
- 6 September 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (9) , 898
Open AccessComparing the Immune Response to PEEK as an Implant Material with and without P-15 Peptide as Bone Graft Material in a Rabbit Long Bone Model
P-15 is a 15-amino-acid-long biomimetic peptide widely demonstrated to enhance osteogenesis in vivo. Despite the prevalence of polyether-ether-ketone (PEEK) in interbody device manufacturing, a growing body of evidence suggests it may produce an unfavorable immune response. The purpose of this preliminary study was to characterize the immune response and new bone growth surrounding PEEK implants with and without a P-15 peptide-based osteobiologic. A bilateral femoral defect model was conducted using New Zealand white rabbits. A total of 17 test subjects received one implant in each distal femur, either with or without bone graft material. Animals were allowed to survive to 4 or 8 weeks, at which time the femurs were collected and subjected to micro-computer tomography (microCT) or cytokine analysis. MicroCT analysis included the quantification of bone growth and density surrounding each implant. The cytokine analysis of periprosthetic tissue homogenates included the quantification of interleukins (ILs) and TNF-α expression via ELISA kits. Improvements in bone volume were observed in the P-15 cohort for the regions of interest, 500–136 and 136–0 µm from the implant surface, at 8 weeks post-op. Concentrations of IL-1β, IL-4, and IL-6 cytokines were significantly higher in the P-15 cohort compared to the PEEK cohort at the 4-week timepoint. Significant reductions in the concentrations of IL-4 and IL-6 cytokines from the 4- to 8-week cohort were observed in the P-15 cohort only. The P-15 peptide has the potential to modulate the immune response to implanted materials. We observed improvements in bone growth and a more active micro-environment in the P-15 cohort relative to the PEEK control. This may indicate an earlier transition from the inflammatory to remodeling phase of healing.
- Open Access
- 11 July 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (7) , 1544
The Categorization of Perinatal Derivatives for Orthopedic Applications
Musculoskeletal (MSK) pathology encompasses an array of conditions that can cause anything from mild discomfort to permanent injury. Their prevalence and impact on disability have sparked interest in more effective treatments, particularly within orthopedics. As a result, the human placenta has come into focus within regenerative medicine as a perinatal derivative (PnD). These biologics are sourced from components of the placenta, each possessing a unique composition of collagens, proteins, and factors believed to aid in healing and regeneration. This review aims to explore the current literature on PnD biologics and their potential benefits for treating various MSK pathologies. We delve into different types of PnDs and their healing effects on muscles, tendons, bones, cartilage, ligaments, and nerves. Our discussions highlight the crucial role of immune modulation in the healing process for each condition. PnDs have been observed to influence the balance between anti- and pro-inflammatory factors and, in some cases, act as biologic scaffolds for tissue growth. Additionally, we assess the range of PnDs available, while also addressing gaps in our understanding, particularly regarding biologic processing methods. Although certain PnD biologics have varying levels of support in orthopedic literature, further clinical investigations are necessary to fully evaluate their impact on human patients.
- 11 July 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (7) , 1544
Open AccessThe Categorization of Perinatal Derivatives for Orthopedic Applications
Musculoskeletal (MSK) pathology encompasses an array of conditions that can cause anything from mild discomfort to permanent injury. Their prevalence and impact on disability have sparked interest in more effective treatments, particularly within orthopedics. As a result, the human placenta has come into focus within regenerative medicine as a perinatal derivative (PnD). These biologics are sourced from components of the placenta, each possessing a unique composition of collagens, proteins, and factors believed to aid in healing and regeneration. This review aims to explore the current literature on PnD biologics and their potential benefits for treating various MSK pathologies. We delve into different types of PnDs and their healing effects on muscles, tendons, bones, cartilage, ligaments, and nerves. Our discussions highlight the crucial role of immune modulation in the healing process for each condition. PnDs have been observed to influence the balance between anti- and pro-inflammatory factors and, in some cases, act as biologic scaffolds for tissue growth. Additionally, we assess the range of PnDs available, while also addressing gaps in our understanding, particularly regarding biologic processing methods. Although certain PnD biologics have varying levels of support in orthopedic literature, further clinical investigations are necessary to fully evaluate their impact on human patients.
- Open Access
- 12 June 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (6) , 599
The Osteogenic Peptide P-15 for Bone Regeneration: A Narrative Review of the Evidence for a Mechanism of Action
Bone regeneration is a complex multicellular process involving the recruitment and attachment of osteoprogenitors and their subsequent differentiation into osteoblasts that deposit extracellular matrixes. There is a growing demand for synthetic bone graft materials that can be used to augment these processes to enhance the healing of bone defects resulting from trauma, disease or surgery. P-15 is a small synthetic peptide that is identical in sequence to the cell-binding domain of type I collagen and has been extensively demonstrated in vitro and in vivo to enhance the adhesion, differentiation and proliferation of stem cells involved in bone formation. These events can be categorized into three phases: attachment, activation and amplification. This narrative review summarizes the large body of preclinical research on P-15 in terms of these phases to describe the mechanism of action by which P-15 improves bone formation. Knowledge of this mechanism of action will help to inform the use of P-15 in clinical practice as well as the development of methods of delivering P-15 that optimize clinical outcomes.
- 12 June 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (6) , 599
Open AccessThe Osteogenic Peptide P-15 for Bone Regeneration: A Narrative Review of the Evidence for a Mechanism of Action
Bone regeneration is a complex multicellular process involving the recruitment and attachment of osteoprogenitors and their subsequent differentiation into osteoblasts that deposit extracellular matrixes. There is a growing demand for synthetic bone graft materials that can be used to augment these processes to enhance the healing of bone defects resulting from trauma, disease or surgery. P-15 is a small synthetic peptide that is identical in sequence to the cell-binding domain of type I collagen and has been extensively demonstrated in vitro and in vivo to enhance the adhesion, differentiation and proliferation of stem cells involved in bone formation. These events can be categorized into three phases: attachment, activation and amplification. This narrative review summarizes the large body of preclinical research on P-15 in terms of these phases to describe the mechanism of action by which P-15 improves bone formation. Knowledge of this mechanism of action will help to inform the use of P-15 in clinical practice as well as the development of methods of delivering P-15 that optimize clinical outcomes.
- 5 June 2024
- Published by Elsevier in The Spine Journal
- Vol. 24 (10) , 1858-1871
Effect of device constraint: a comparative network meta-analysis of ACDF and cervical disc arthroplasty
- 5 June 2024
- Published by Elsevier in The Spine Journal
- Vol. 24 (10) , 1858-1871
Effect of device constraint: a comparative network meta-analysis of ACDF and cervical disc arthroplasty